While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

By Hugo Francisco de Souza New research reveals that vaccines enhanced with the AS01 adjuvant may help shield the aging brain ...

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

HSS’ newly formed Advisory Committee on Immunization Practices voted 5-2 to recommend Merck’s respiratory syncytial virus monoclonal antibody drug and against an ingredient in some flu vaccines. The ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.